CNTB CONNECT BIOPHARMA HLDGS LTD

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:00 a.m. ET.

The live webcast of the presentation may be accessed via the Investors section of the Connect website at . An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit .

Investor Relations Contact:

Alex Lobo

Precision AQ



(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC





(858) 717-2310 or (646) 942-5604



EN
03/03/2026

Underlying

CNTBCONNECT BIOPHARMA HLDGS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONNECT BIOPHARMA HLDGS LTD

 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Reports 2025 Full-Year Financial Results and Provide...

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update – Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into secon...

March 31, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Announces $20.2 Million Private Placement Financing

Connect Biopharma Announces $20.2 Million Private Placement Financing Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of ...

March 30, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic De...

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limit...

March 30, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Announces Positive Topline Data from its Phase 1 Stu...

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique benefic...

March 30, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopi...

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Compa...

March 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch